Related Experiment Video
Updated: Jul 20, 2026
05:52
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
Sentinel lymph node biopsy for breast cancer: current controversies
1Department of General Surgery, Istanbul Medical School, Istanbul University, Istanbul, Turkey. vozmen@istanbul.edu.tr
The Breast Journal
|September 9, 2006
Summary
Sentinel lymph node biopsy (SLNB) is a reliable alternative to axillary lymph node dissection for early-stage breast cancer. Ongoing research addresses controversies and refines SLNB
Area of Science:
- Oncology
- Surgical Pathology
Background:
- Sentinel lymph node biopsy (SLNB) has largely replaced axillary lymph node dissection (ALND) for node-negative T1-T2 breast cancer.
- SLNB demonstrates high accuracy in predicting axillary nodal status with a false-negative rate below 10%.
Purpose of the Study:
- To address controversies surrounding SLNB, including technical aspects, lymphoscintigraphy, internal mammary node biopsy, patient selection, staging accuracy, and post-procedure management.
- To discuss updated staging criteria (AJCC 2002) and recent guideline recommendations (ASCO 2005) impacting SLNB interpretation.
Main Methods:
- Review of current literature and guideline recommendations.
- Discussion of technical considerations and pathological evaluation methods (hematoxylin-eosin, immunohistochemistry).
Main Results:
- SLNB is a highly predictive procedure for axillary nodal status.
- The evaluation of internal mammary lymph nodes and micrometastases is crucial for accurate staging.
Conclusions:
- SLNB is a valuable tool in breast cancer axillary staging, offering reduced morbidity compared to ALND.
- Long-term follow-up data will further clarify the prognostic significance and clinical utility of SLNB.
